Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Study Director - Torben Plesner, MD
Vejle Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Copenhagen Ø, Denmark
- Facility name not stated
Vejle, Denmark
- Facility name not stated
Lille, France
- Facility name not stated
Nantes, France
- Facility name not stated
Vandœuvre-lès-Nancy, France
- Facility name not stated
Utrecht, Netherlands
- Facility name not stated
London, United Kingdom
- Facility name not stated
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jun 2012
- Primary completion
- 2 Oct 2015
- Completion
- 23 Oct 2024
- Last update posted
- 16 Mar 2026
- Registered enrollment
- 45
- Registry id
- NCT01615029
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.